immunoglobulin heavy variable (III)-22-2 (pseudogene)Genealiases: 3-22.2P · IGHVIII222
Q-omics provides the consensus-scored IGHVIII-22-2 profile across patient tissues and cancer cell-line models. IGHVIII-22-2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, IGHVIII-22-2 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, IGHVIII-22-2 RNA expression shows 7,188 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, COAD, and THYM as cancer lineages where IGHVIII-22-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHVIII-22-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHVIII-22-2 survival associations across molecular data types. IGHVIII-22-2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHVIII-22-2 RNA expression–survival associations across cancer types. High IGHVIII-22-2 expression shows unfavorable associations in KIRP, STAD, KIRC, DLBC and MESO, but favorable associations in COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for IGHVIII-22-2 RNA expression.
This table summarizes IGHVIII-22-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGHVIII-22-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHVIII-22-2 shows lower tumor expression in COAD and HNSC. The COAD box plot shows higher IGHVIII-22-2 RNA expression in normal versus tumor tissue (log2 FC = −0.758, t-test p < 0.001).
This table shows molecular features associated with IGHVIII-22-2 in patient tissues and cancer cell lines. In patient samples, IGHVIII-22-2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
